• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: LIVANOVA CANADA CORP PERCEVAL SUTURELESS AORTIC HEART VALVE; TISSUE HEART VALVES

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

LIVANOVA CANADA CORP PERCEVAL SUTURELESS AORTIC HEART VALVE; TISSUE HEART VALVES Back to Search Results
Model Number PVS27
Device Problem Patient-Device Incompatibility (2682)
Patient Problem Complete Heart Block (2627)
Event Type  Injury  
Event Description
The manufacturer was informed on this event through the publication 'sutureless valve replacement through a right anterior mini-thoracotomy in elderly patients with stenotic bicuspid aortic valve' by durdu et al.This paper reports a single-center experience with the perceval s valve and retrospectively analyses data for 13 patients with a stenotic bicuspid aortic valve (bav).From january 2013 through march 2018, 13 patients with severe aortic stenosis involving bav underwent sutureless aortic valve replacement (su-avr) with the perceval-s.The central message of this paper is that su-avr is a technically feasible and safe procedure in as patients involving bav anatomy with acceptable good surgical outcomes.Among the results presented, it is mentioned that one patient (7.6%) required permanent pacemaker implantation due to a third-degree atrioventricular block.
 
Event Description
The manufacturer was informed on this event through the publication 'sutureless valve replacement through a right anterior mini-thoracotomy in elderly patients with stenotic bicuspid aortic valve' by durdu et al.This paper reports a single-center experience with the perceval s valve and retrospectively analyses data for 13 patients with a stenotic bicuspid aortic valve (bav).From january 2013 through march 2018, 13 patients with severe aortic stenosis involving bav underwent sutureless aortic valve replacement (su-avr) with the perceval-s.The central message of this paper is that su-avr is a technically feasible and safe procedure in as patients involving bav anatomy with acceptable good surgical outcomes.Among the results presented, it is mentioned that one patient (7.6%) required permanent pacemaker implantation due to a third-degree atrioventricular block.Per additional information received, pre-operatively the patient was in sinus rhythm and very symptomatic (nhya class iv) due to highly stenotic type 0 bicuspid aortic valve.The native valve was excised and complete decalcification was performed.The perceval pvs27 was safely implanted.On postoperative day 9, the patient experienced a third-degree av block and a permanent pacemaker was implanted.In the follow-up, the patient is reportedly still very well with a dramatic improvement of the cardiac functions, despite the pace rhythm.Based on the assessment received from the field, the main reason for the pacemaker implant was attributed to the need to perform a complete decalcification of the severe stenotic bicuspid aortic valve.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
PERCEVAL SUTURELESS AORTIC HEART VALVE
Type of Device
TISSUE HEART VALVES
Manufacturer (Section D)
LIVANOVA CANADA CORP
5005 north fraser way
burnaby, british columbia
MDR Report Key9448656
MDR Text Key170324356
Report Number1718850-2019-01204
Device Sequence Number1
Product Code LWR
Combination Product (y/n)N
Number of Events Reported1
Summary Report (Y/N)N
Report Source Distributor
Type of Report Initial,Followup
Report Date 11/12/2019,01/15/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberPVS27
Device Catalogue NumberICV1211
Was Device Available for Evaluation? No
Was the Report Sent to FDA? No
Distributor Facility Aware Date11/12/2019
Event Location Hospital
Date Report to Manufacturer11/12/2019
Initial Date Manufacturer Received Not provided
Initial Date FDA Received12/10/2019
Supplement Dates Manufacturer Received11/12/2019
Supplement Dates FDA Received01/15/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age75 YR
-
-